Dupilumab is in clinical development as an add-on to controller medications for the maintenance treatment in children aged 6 up to 12 years with uncontrolled, moderateto-severe asthma. Asthma is a common lung condition that causes wheezing, coughing and breathlessness. Individuals with asthma can suffer an asthma attack, which in severe cases can be fatal. Patients with severe asthma have ongoing daily symptoms despite high-intensity asthma treatment. Therefore, there is need for additional treatment strategies which includes a need for biological therapies. Dupilumab is a targeted biological therapy that is taken subcutaneously. It acts by blocking certain proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13) and mediates the pathways involved in the inflammatory process in asthma. If licensed, dupilumab will offer an additional add-on maintenance treatment option for children aged 6 up to 12 years with moderate-to-severe asthma that is uncontrolled on current treatment.